Cancer Society. Cancer Facts American,Figs American,2017.html Aziz Z,Iqbal J,Akram M,Saeed S M .2007 .Treatment of chronic myeloid leukemia in the imatinib era: Perspective from a developing country. Cancer, 109(6) : 1138-1145.
Baccarani M,Castagnetti F,Gugliotta G,Rosti G .2015 .A review of the European LeukemiaNet recommendations for the management of CML. , 94(2) : 141-147.
Baccarani M,Deininger MW,Rosti G,Hochhaus A,Soverini S,Apperley JF,Cervantes F,Clark RE,Cortes JE,Guilhot F,Hjorth-Hansen H,Hughes TP,Kantarjian HM,Kim DW,Larson RA,Lipton JH,Mahon FX,Martinelli G,Mayer J,Müller MC,Niederwieser D,Pane F,Radich JP,Rousselot P,Saglio G,Saußele S,Schiffer C,Silver R,Simonsson B,Steegmann JL,Goldman JM,Hehlmann R JM .2013 .European Leukemia Net recommendations for the management of chronic myeloid leukemia. Blood, 122(6) : 872-884.
Baccarani M,Saglio G,Goldman J,Hochhaus A,Simonsson B,Appelbaum F,Apperley J,Cervantes F,Cortes J,Deininger M,Gratwohl A,Guilhot F,Horowitz M,Hughes T,Kantarjian H,Larson R,Niederwieser D,Silver R,Hehlmann R,European Leukemia Net R .2006 .Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. , 108(6) : 1809-1820.
Beinortas T,Tavorienė I,Zvirblis T,Gerbutavičius R,Jurgutis M,Griskevicius L M .2016 .Chronic myeloid leukemia incidence, survival and accessibility oftyrosine kinase inhibitors: A report from populationbased Lithuanian hematological disease registry 2000- 2013. , 16 : 198.
Ben Lakhal R,Ghedira H,Bellaaj H,Ben Youssef Y,Menif S,Manai Z,Bedoui M,Lakhal A,M'Sadek F,Elloumi M,Khélif A,Ben Romdhane N,Laatiri MA,Meddeb B .2018 .Chronic myeloid leukemia patients in Tunisia: Epidemiology and outcome in the imatinib era (a multicentric experience). , 97(4) : 597-604.
Cohen MH,Williams G,Johnson JR,Duan J,Gobburu J,Rahman A,Benson K,Leighton J,Kim SK,Wood R,Rothmann M,Chen G,Staten U KM,Pazdur AM,R AM .2002 .Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer Res., 8(5) : 935-942.
Kantarjian H Cortes J .2012 .How I treat newly diagnosed chronic phase CML. , 120(7) : 1390-1397.
Cortes JE,Talpaz M,O'Brien S,Faderl S,Garcia-Manero G,Ferrajoli A,Verstovsek S,Rios MB,Shan J,Kantarjian HM .2006 .Staging of chronic myeloid leukemia in the imatinib era: An evaluation of the World Health Organization proposal. Cancer, 106(6) : 1306-1315.
Deininger M,O'Brien S,Guilhot F,Goldman JM,Hochhaus A,Hughes TP,Radich JP,hatfiedl AK,Mone M,Filian J,Reynolds J,Gathmann I,Larson RA,Druker BJ .2009 .International randomized study of interferon and STI571 (IRIS) 8-year follow-up: Sustained survival and low risk for progression in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib. Blood, 14(22) : 1126.
Funke VAM,Medeiro CR,Lima DH,Setúbal DC,Bitencourt MA,Bonfim CM,Ruiz J,Neto JZ,Pasquini R,Gambacorti-Passerini C,Piazza R C .2015 .Imatinib-A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015. , 1(2) : 143-144.
Gugliotta G,Castagnetti F,Palandri F,Breccia M,Intermesoli T,Capucci A,Martino B,Pregno P,Rupoli S,Ferrero D,Gherlinzoni F,Montefusco E,Bocchia M,Tiribelli M,Pierri I,Grifoni F,Marzocchi G,Amabile M,Testoni N,Martinelli G,Alimena G,Pane F,Saglio G,Baccarani M,Rosti G .2011 .Frontline imatinib treatment of chronic myeloid leukemia: No impact of age on outcome, a survey by the GIMEMA CML Working Party. , 117(21) : 5591-5599.
Gupta A,Prasad K A .2007 .Hematological and molecular response evaluation of CML patients on imatinib. J Assoc Physicians India, 55 : 109-113.
Hasford J,Baccarani M,Hoffmann V,Guilhot J,Saussele S,Rosti G,Guilhot F,Porkka K,Ossenkoppele G,Lindoerfer D,Simonsson B,Pfirrmann M,Hehlmann R M .2011 .Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: The EUTOS score. Blood, 118(3) : 686-692.
Hasford J,Pfirrmann M,Hehlmann R,Allan NC,Baccarani M,Kluin-Nelemans JC,Alimena G,Steegmann JL,Ansari H JL .1998 .Writing Committee for the Collaborative CML Prognostic Factors Project Group. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J. Natl. Cancer Inst., 90(11) : 850-858.
Haznedaroglu IC .2013 .Current concerns of under treatment and overtreatment in chronic myeloid leukemia based on European LeukemiaNet 2013 recommendations. , 14(15) : 2005-2010.
Haznedaroglu IC .2014 .Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML). Mediterr. J. Hematol. Infect Dis, 6(1) : e2014009.
Hochhaus A,Larson RA,Guilhot F,Radich JP,Branford S,Hughes TP,Baccarani M,Deininger MW,Cervantes F,Fujihara S,Ortmann CE,Menssen HD,Kantarjian H,O'Brien SG,Druker BJ,IRIS Investigators BJ .2017 .Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N. Engl. J. Med, 376(10) : 917-927.
Huang X,Cortes J,Kantarjian H J .2012 .Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer, 118(12) : 3123-3127.
Kantarjian H,Shah NP,Hochhaus A,Cortes J,Shah S,Ayala M,Moiraghi B,Shen Z,Mayer J,Pasquini R,Nakamae H,Huguet F,Boque C,Chuah C,Bleickardt E,Bradley-Garelik MB,Zhu C,Szatrowski T,Shapiro D,Baccarani M .2010 .Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med, 362(24) : 2260-2270.
Kantarjian H,Talpaz M,O'Brien S,Giles F,Faderl S,Verstovsek S,Garcia-Manero G,Shan J,Rios MB,Champlin R,de Lima M,Cortes J .2005 .Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia-- comparison with historic experience. Cancer, 103(10) : 2099-2108.
Meier Kaplan E,P Kaplan E .1958 .Nonparanietric estimation from incomplete observations. J. Amer. Statist Assn, 53(282) : 457-481.
Kuntegowdanahalli LC,Kanakasetty GB,Thanky AH,Dasappa L,Jacob LA,Mallekavu SB,Lakkavalli RK,Kadabur LN,Haleshappa RA .2016 .Prognostic and predictive implications of Sokal, Euro and EUTOS scores in chronic myeloid leukaemia in the imatinib era-experience from a tertiary oncology center in Southern India. Ecancermedical. Science, 10 : 679.
Marin D,Morra E,Michallet M,Hellmann A,Niederwieser D,Schloegl E,Björeman M,Foryciarz K,Ho AY,Kuliczkowski K,Ossenkoppele G,Gozzini A,Guerra ML,Verhoef G,Mori A Pans M M,Steegmann JL M .2011 .Effect of Time to Dasatinib Initiation on Outcome of ImatinibIntolerant Patients with Chronic-Phase Chronic Myelogenous Leukemia (CP-CML): Results from a European Observational Study (FORTE. , 118(21) : 1689-211.
Massoud M,Sakr R,Kerbage F,Makdissi J,Hawi J,Rached L,Nasr F,Chahine G F .2017 .Analysis of survival of patients with chronic myeloid leukemia treated with imatinib in the last 15 years in Lebanon. Clin Lymphoma Myeloma Leuk. , : S111-S115.
Mottalib MA,Sultana TA,Khalil MI,Gan SH,Islam MS,Choudhury S . .Phase distribution of chronic myeloid leukemia in Bangladesh. BMC Res Notes, 13(7) : 142.
Nair V,Sharma A,Kotwal J,Bhikshapathy M,Mishra DK,Das S,Sharma S,Kapoor R,Singh J,Nair V,Uday Y,Kotwal A .2014 .Monitoring of response to therapy with imatinib mesylate in Chronic Myeloid Leukemia in chronic phase (CML-CP). Med. J. Armed. Forces India, 70(4) : 315-320.
O'Brien SG,Guilhot F,Larson RA,Gathmann I,Baccarani M,Cervantes F,Cornelissen JJ,Fischer T,Hochhaus A,Hughes T,Lechner K,Nielsen JL,Rousselot P,Reiffers J,Saglio G,Shepherd J,Simonsson B,Gratwohl A,Goldman JM,Kantarjian H,Taylor K,Verhoef G,Bolton AE,Capdeville R,Druker BJ,IRIS Investigators BJ .2003 .Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl. J. Med, 348(11) : 994-1004.
Ota S,Matsukawa T,Yamamoto S,Ito S,Shindo M,Sato K,Kondo T,Kohda K,Sakai H,Mori A,Takahashi T,Ikeda H,Kuroda H,Haseyama Y,Yamamoto M,Sarashina T,Yoshida M,Kobayashi R,Nishio M,Ishihara T,Hirayama Y,Kakinoki Y,Kobayashi H,Fukuhara T,Imamura M,Kurosawa M M .2018 .Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia. Eur. J. Haematol., 101(1) : 95-105.
Palandri F,Iacobucci I,Castagnetti F,Testoni N,Poerio A,Amabile M,Breccia M,Intermesoli T,Iuliano F,Rege-Cambrin G,Tiribelli M,Miglino M,Pane F,Saglio G,Martinelli G,Rosti G,Baccarani M .2008 .Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome. , 93(5) : 770-774.
Reavie L,Buckley SM,Loizou E,Takeishi S,ArandaOrgilles B,Ndiaye-Lobry D,Abdel-Wahab O,Ibrahim S,Nakayama KI,Aifantis I .2013 .Regulation of cMyc ubiquitination controls chronic myelogenous leukemia initiation and progression. Cancer Cell, 23(3) : 362-75.
Rumpold H and Webersinke G .2011 .Molecular pathogenesis of Philadelphia-positive chronic myeloid leukemia - is it all BCR-ABL? Curr. Cancer Drug Targets, 11(1) : 3-19.
Saussele S,Krauss MP,Hehlmann R,Lauseker M,Proetel U,Kalmanti L,Hanfstein B,Fabarius A,Kraemer D,Berdel WE,Bentz M,Staib P,de Wit M,Wernli M,Zettl F,Hebart HF,Hahn M,Heymanns J,Schmidt-Wolf I,Schmitz N,Eckart MJ,Gassmann W,Bartholomaus A,Pezzutto A,Leibundgut EO,Heim D,Krause SW,Burchert A,Hofmann WK,Hasford J,Hochhaus A,Pfirrmann M,Müller MC .2015 .Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood, 126(1) : 42-49.
Sneed TB,Kantarjian HM,Talpaz M,O'Brien S,Rios MB,Bekele BN,Zhou X,Resta D,Wierda W,Faderl S,Giles F,Cortes JE .2004 .The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer, 100(1) : 116-121.
Sokal JE,Cox EB,Baccarani M,Tura S,Gomez GA,Robertson JE,Tso CY,Braun TJ,Clarkson BD,Cervantes F BD .1984 .Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood, 63(4) : 789-799.
Su XY,Wong N,Cao Q,Yu LZ,Niu C,Wickham N,Johnson PJ,Chen Z,Chen SJ .1999 .Chromosomal aberrations during progression of chronic myeloid leukemia identified by cytogenetic and molecular cytogenetic tools:. Implication of 1q12-21. Cancer Genet, 108(1) : 6-12.
Usmani SZ,Yunus SA,Jamal Y .2009 .Overview of chronic myeloid leukemia patients in Pakistan in the pre-imatanib era. Asian Pac. J. Cancer Prev, 10(6) : 1039-1040.
Wang W,Cortes JE,Tang G,Khoury JD,Wang S,Bueso-Ramos CE,DiGiuseppe JA,Chen Z,Kantarjian HM,Medeiros LJ,Hu S LJ .2016 .Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood, 127(22) : 2742-2750.
Yamamoto E,Fujisawa S,Hagihara M,Tanaka M,Fujimaki K,Kishimoto K,Hashimoto C,Itabashi M,Ishibashi D,Nakajima Y,Tachibana T,Kawasaki R,Kuwabara H,Koharazawa H,Yamazaki E,Tomita N,Sakai R,Fujita H,Kanamori H,Ishigatsubo Y H .2014 .European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients. Cancer Sci., 105(1) : 105-109.